瑞典的医源性血管损伤-EuropeanJournalofVascularand.PDF

H. Rudström,* D. Bergqvist, M. Ögren and M. Björck Institution of Surgical Sciences, Depar tment of Vascular Surgery, Upp sala University Hospi tal, Sweden 1987-2005Swedvasc 185348% 29% 23% 6835401987-2005 1.21.641% 51% (4.9%)2.5% 58%44% 18% 888 37% 39% 19% 19874.6%200515% Meta P. De Rango, P. Cao,* G. Parlani, F. Verzini and D. Brambilla Division of Vascular and Endovascular Surgery, University of Perugia, Ospe dale S. Maria della Misericordia, Perugia, Italy 5.5cm) 24 57735 OR 0.68; 95% CI 0.51-0.90,OR 0.77; 95% CI 0.69 to 0.86 , OR 0.58; 95% CI 0.40 - 0.87 OR 0.61; 95% CI 0.47 to 0.79 Behcet ’s 1 4 1 2 1 3 T.-W. Kwon, * S.-J. Park, H.-K. Kim, H.-K. Yoon, G.-E. Kim and B. Yu 1. Division of Vascular Surgery, Depar tment of Surgery, 2. Division of Interventional Radiology, Depar tment of Radiology, 3. Division of Rheumatology, Depar tment of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea, and 4. Depa rtment of Surgery, University of Ulsan College of Medicine and Ulsan University Hospi tal, Ulsan, Korea Marfan G. Mommertz,1 F. Sigala,1 S. Langer,1 T.A. Koeppel,1 W.H. Mess,3 2 2 G.W.H. Schurink and M.J. Jacobs1, * European Vascular Center Aachen-Maastricht, 1. Depa rtment of Vascular Surgery, University Hospi tal Aachen, Germany, Depa rtments of 2. Vascular Surgery, and 3. Neurophysiology, University Hospi tal Maastricht, The Netherlands Marfan(DTAA)(TAAA) 206 22Marfan18-5740 612 11II23 4III1IVA n=6 Bn= 1615Bentall n=7 n=8 125 mmol/L130 mmol/L 92 mmol/L 1.5 0.33-30 n = 1n =2 n = 2 n = 138CT II6 Marfan Marfan PS: Marfan Syndrome